Knight Therapeutics (TSE:GUD) Trading Down 1% – Here’s Why

Shares of Knight Therapeutics Inc. (TSE:GUD) were down 1% during mid-day trading on Friday . The company traded as low as C$5.88 and last traded at C$5.91. Approximately 20,757 shares changed hands during trading, a decline of 69% from the average daily volume of 66,793 shares. The stock had previously closed at C$5.97.

Knight Therapeutics Stock Down 1.0%

The firm has a 50 day moving average of C$6.03 and a two-hundred day moving average of C$6.09. The stock has a market capitalization of C$586.80 million, a PE ratio of -147.75, a P/E/G ratio of -1,013.50 and a beta of -0.01. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Knight Therapeutics (TSE:GUD) last posted its earnings results on Thursday, November 6th. The company reported C($0.04) earnings per share for the quarter. Knight Therapeutics had a negative net margin of 8.81% and a negative return on equity of 4.04%. The firm had revenue of C$122.63 million during the quarter. Equities research analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.